- Home
- WING vs MRNA Comparison
WING vs MRNA Comparison
Compare WING & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WING
- MRNA
- Stock Information
- Founded
- WING 1994
- MRNA 2010
- Country
- WING United States
- MRNA United States
- Employees
- WING N/A
- MRNA N/A
- Industry
- WING Restaurants
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WING Consumer Discretionary
- MRNA Health Care
- Exchange
- WING Nasdaq
- MRNA Nasdaq
- Market Cap
- WING 9.0B
- MRNA 10.6B
- IPO Year
- WING 2015
- MRNA 2018
- Fundamental
- Price
- WING $341.70
- MRNA $26.56
- Analyst Decision
- WING Strong Buy
- MRNA Hold
- Analyst Count
- WING 19
- MRNA 19
- Target Price
- WING $339.05
- MRNA $48.13
- AVG Volume (30 Days)
- WING 809.4K
- MRNA 14.2M
- Earning Date
- WING 07-30-2025
- MRNA 05-01-2025
- Dividend Yield
- WING 0.32%
- MRNA N/A
- EPS Growth
- WING 110.47
- MRNA N/A
- EPS
- WING 5.91
- MRNA N/A
- Revenue
- WING $651,112,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- WING $18.50
- MRNA N/A
- Revenue Next Year
- WING $17.68
- MRNA $8.98
- P/E Ratio
- WING $57.83
- MRNA N/A
- Revenue Growth
- WING 30.98
- MRNA N/A
- 52 Week Low
- WING $204.00
- MRNA $23.15
- 52 Week High
- WING $433.86
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- WING 77.06
- MRNA 50.60
- Support Level
- WING $315.78
- MRNA $25.22
- Resistance Level
- WING $345.66
- MRNA $27.15
- Average True Range (ATR)
- WING 10.64
- MRNA 1.61
- MACD
- WING 1.82
- MRNA 0.26
- Stochastic Oscillator
- WING 94.42
- MRNA 47.66
About WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, reaching north of 2,560 global stores at the end of 2024. With a 98% franchised model, Wingstop generates the lion share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.